Zura Bio Limited Class A Ordinary Shares

NASDAQ:ZURA USA Biotechnology
Market Cap
$418.75 Million
Market Cap Rank
#14651 Global
#5859 in USA
Share Price
$6.44
Change (1 day)
+2.55%
52-Week Range
$1.00 - $7.04
All Time High
$33.21
About

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more

Zura Bio Limited Class A Ordinary Shares (ZURA) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -0.130x

Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) has a cash flow conversion efficiency ratio of -0.130x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.44 Million) by net assets ($118.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zura Bio Limited Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Zura Bio Limited Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Zura Bio Limited Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zura Bio Limited Class A Ordinary Shares ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Zura Bio Limited Class A Ordinary Shares (2021–2024)

The table below shows the annual cash flow conversion efficiency of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $160.02 Million $-28.08 Million -0.175x +7.28%
2023-12-31 $79.55 Million $-15.05 Million -0.189x -447.24%
2022-12-31 $-22.06 Million $-1.20 Million 0.054x +746.14%
2021-12-31 $130.20 Million $-1.10 Million -0.008x --